Market Place
Sourcing Support
Acurx Publishes Data On Ibezapolstat`s Gut Microbiome Effects
03 Mar 2025 //
PR NEWSWIRE
Acurx publishes positive results on Ibezapolstat for CDI.
24 Feb 2025 //
PR NEWSWIRE
Acurx Gets EMA Guidance For Ibezapolstat Ph3 For C. Difficile
06 Jan 2025 //
PR NEWSWIRE
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile
09 Dec 2024 //
PR NEWSWIRE
Acurx Announces Ibezapolstat And ACX-375 Results in CDI
26 Sep 2024 //
PR NEWSWIRE
Acurx Shares Ibezapolstat Research at International C. difficile Symposium
24 Sep 2024 //
PR NEWSWIRE
HotSpot To Present Phase 1 Data On CBL-B Inhibitor At ESMO 2024
17 Jul 2024 //
PR NEWSWIRE
Acurx Presents Ibezapolstat Phase 2 Results For CDI At Scientific Conference
15 Jul 2024 //
PR NEWSWIRE
Acurx Announces Successful Ibezapolstat Phase 2 Meeting, Phase 3 Readiness
15 May 2024 //
PR NEWSWIRE
Acurx Presents Ibezapolstat Phase 2 Results At ESCMID 2024
02 May 2024 //
PR NEWSWIRE
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat
27 Feb 2024 //
PR NEWSWIRE
Acurx Announces Positive Clinical Cure Data for Ibezapolstat from Phase 2b Trial
29 Jan 2024 //
PR NEWSWIRE
Acurx Announces Positive Microbiology and Microbiome Data for Ibezapolstat
17 Jan 2024 //
PR NEWSWIRE
Acurx Announces Positive Phase 2b Results with Ibezapolstat
11 Dec 2023 //
PR NEWSWIRE
Acurx Announces Ibezapolstat Ph 2 Efficacy Results with 96% Clinical Cure Rate
02 Nov 2023 //
PR NEWSWIRE
Acurx Announces Ibezapolstat Scientific Posters and Presentations
19 Oct 2023 //
PR NEWSWIRE
Acurx Announces Completion and Early Discontinuation of the Ibezapolstat
02 Oct 2023 //
PR NEWSWIRE
Acurx Pharma Reports 1Q 2023 Results and Provides Business Update
12 May 2023 //
PR NEWSWIRE
FDA Accepts Interim Analysis Plan for Ongoing Ph2b Ibezapolstat Clinical Trial
11 Apr 2023 //
PR NEWSWIRE
Acurx Announces New Data Presentations from Ongoing PII Trial of Ibezapolstat
02 Aug 2022 //
PRNEWSWIRE
Acurx Announces New Microbiome Data from Its Ph2aTrial of Ibezapolstat
01 Nov 2021 //
PRNEWSWIRE
Acurx Presents Positive Ibezapolstat Microbiome Data at IDWeek
04 Oct 2021 //
PRNEWSWIRE
Acurx Announces All Patients Demonstrated Clinical and Sustained Cure in Ph2A
05 Nov 2020 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.